Corcept Therapeutics Incorporated has grown revenue 25% a year over three years and 19% a year over five, with earnings per share compounding at −20%. Revenue growth, 3-year annual rate: +25% (Biotechnology median +17%). Revenue growth, 5-year rate: +19%, growth has picked up over the last three years. Earnings per share, 3-year rate: −20%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 26, FY2000 to FY2025, as filed.

CORTCorcept Therapeutics Incorporated

Healthcare

$121.12+50% 1Y

$121.12

$32.1552 weeks$123.53

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +16% year on year, but earnings down −63% year on year and operating margin narrowing (−15.5 points).

1 good, 2 to watch

Revenue trend+16% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +19% a year.

Earnings trend−63% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−15.5 points operating

Trailing-twelve-month operating margin, -1.7% now against 13.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 9% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is CORT growing?

Corcept Therapeutics Incorporated has grown revenue 25% a year over three years and 19% a year over five, with earnings per share compounding at −20%.

+25%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +19%
Revenue growth, 5-year rate · +25% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −20%
Earnings per share, 3-year rate · revenue +25% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 26
Years of annual history on file · FY2000 to FY2025, as filed